Innate Pharma to Participate in Jefferies Global Healthcare Conference 2026
Innate Pharma S.A. (Nasdaq: IPHA), a clinical-stage biotechnology company specializing in cancer immunotherapies, announced that members of its executive management team will participate in the Jefferies Global Healthcare Conference 2026. The event is scheduled to take place from June 2β4, 2026, in New York City. During the conference, the company's leadership will engage in one-on-one meetings with institutional investors. Innate Pharma's current development portfolio highlights several key assets, including IPH4502 (a Nectin-4 antibody-drug conjugate for solid tumors), lacutamab (an anti-KIR3DL2 antibody for T-cell lymphomas), and monalizumab (an anti-NKG2A antibody being developed in collaboration with AstraZeneca for non-small cell lung cancer). The company also maintains strategic partnerships with Sanofi. This filing serves as a routine notification of investor relations activity and does not disclose any new clinical data or material changes to the company's operations or financial standing.